This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Valerio, G. Articles by Grazia D'Agostino, A. Search for Related Content PubMed PubMed Citation Articles by Valerio, G. Articles by Grazia D'Agostino, A. Social Bookmarking                         What's this?

Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease

Ospedale "Ninetto Melli", Divisione di Pneumologia, 2P Via Lecce 246, San Pietro V.co (Brindisi), Italy 72027, valeriospinosa{at}libero.it

Pierluigi Bracciale

Ospedale "Ninetto Melli", Pneumologia, Antonio Blasi, San Pietro V.co, Italy

Anna Grazia D'Agostino

Ospedale "Ninetto Melli", Divisione di Radiology, San Pietro V.co, Italy

Background: Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) is mainly determined by hypoxemia under respiratory failure by means of the functional hypoxemic vasoconstrictor response. Organic changes of vessels, pulmonary vascular remodelling, is gaining increasing relevance. An imbalance of endothelial products takes place with overload of vasoconstrictors and thrombogenic autacoids over vasodilators and anticoagulant factors. Among vasoconstrictors, endothelin is claimed to be an important factor. Our aim is to assess the effect of the anti-endothelin drug Bosentan on pulmonary hemodynamics and lung function in patients affected by COPD and PH.

Methods: Bosentan was administered to 16 patients for a period of 18 months, while another 16 patients with overlapping features was used as a control group. Pulmonary function test, hemodynamics, effort performance, dyspnoea ratings and quality of life were recorded at the beginning and after 18 months under stable state.

Results: Bosentan treatment resulted in a significant improvement of PH from 37 + 5 to 31 + 6mm Hg and pulmonary vascular resistance from 442 + 192 to 392 + 180dynes cm² and 6MWD from 256 + 118 to 321 + 122m and BODE index from 6.6 + 2.8 to 5.5 + 3U. The effect was most striking in the 30% of patients in GOLD stage III and IV. Most patients in stage IV did not improve, but in all patients the treatment stopped the progressive worsening of hemodynamics over time. The study also highlights the need to identify patients with high pulmonary arterial pressure contrasting with moderate respiratory disease stages, in whom the predominant problem is evidently vascular disease.

Conclusion: This preliminary report suggests that the use of Bosentan in the treatment of PH in COPD is beneficial.

Key Words: COPD • pulmonary arterial hypertension • respiratory failure • bosentan

Therapeutic Advances in Respiratory Disease, Vol. 3, No. 1, 15-21 (2009)
DOI: 10.1177/1753465808103499


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?